Volume 1 number 1 Summer 2003
Special issue for the abstracts of the 7th Pan Arab Conference on Diabetes
PACD7 , 25 – 28 March 2003 Cairo

Abstract Number : 83
The dysmetabolic syndrome,Where are we?

Lobna F. El -Tooney 
Assistant Professor,Internal Medicine, Endocrinology Unit,Assuit University,Egypt 

Recent data show that the prevalence of type II diabetes is rapidly increasing in the world .People are also developing DM at a younger age ,and this trend is likely to continue with increasing prevalence of obesity in the adolescent and youth years.DM has clearly become a major public health issue and it is likely to result in a new epidemic of premature coronary artery disease in the new millennium. The increased risk of atherosclerosis and cardiovascular complications in diabetic patients is related to the frequently associated dyslipidemia ,hypertension ,hyperglycemia ,hyperinsulinemia ,and obesity ,the so called

      DYSMETABOLIC SYNDROME
The Dysmetabolic Syndrome is mostly programmed in utero ;the Thrifty Phenotype Hypothesis.Moreover the different metabolic abnormalities associated with the Dysmetabolic Syndrome are strongly inherited ;the Thrifty Genotype Hypothesis. 
It has been suggested that insulin resistance ,the key abnormality in type II diabetes ,often precedes clinical features of diabetes by 5-6 years. Careful attention to the criteria described for the Dysmetabolic syndrome should help identify those at risk at an early stage .The application of nonpharmacologic as well as new emerging pharmacologic therapies can have beneficial effects in individuals with Dysmetabolic syndrome and /or diabetes mellitus.Early identification and implementation of appropriate therapeutic strategies would be necessary to contain the emerging new epidemic of cardiovascular disease related to diabetes.

OnlineDiabetes Journal, All rights reserved